Cytogen, Inc.
- Medical device or technology
- Synthesis, analytic, diagnostic services
- Diagnostics
At CytoGen, Inc., we have developed a proprietary technology that enables the rapid isolation of viable circulating tumor cells (CTCs) from whole blood in under 30 minutes using our HDM chip and automated system. This innovation allows for high-quality molecular, genomic, and proteomic analyses using live CTCs.
The ability to extract RNA, DNA, and proteins from viable CTCs enables a wide range of applications in drug development and clinical oncology. These include:
- Personalized therapy through selection of targeted drugs based on patient-specific tumor profiles
- Patient stratification in clinical trials
- Monitoring treatment response and resistance
- Longitudinal MRD (minimal residual disease) tracking
Moreover, live CTCs can be used to generate patient-derived organoid cultures for functional drug testing. These organoids may also serve as the basis for in vivo models, further supporting drug validation and resistance studies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}